Evidence map›Paper›PMID 38534945›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report.

Hiroo Imai, Ken Saijo, Noriko Takenaga, Keigo Komine, Kota Ouchi, Yuki Kasahara, Shiori Ishikawa, Keiju Sasaki, Yuya Yoshida, Hidekazu Shirota and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hiroo ImaiDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Ken SaijoDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Noriko TakenagaDepartment of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
Keigo KomineDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Kota OuchiDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Yuki KasaharaDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Shiori IshikawaDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Keiju SasakiDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.ORCID 0000-0002-8270-2107
Yuya YoshidaDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.ORCID 0000-0001-8560-9760
Hidekazu ShirotaDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Masanobu TakahashiDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.
Chikashi IshiokaDepartment of Medical Oncology, Tohoku University Hospital, Sendai 980-8547, Japan.ORCID 0000-0002-3023-1227
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chylous ascites is a rare form of ascites with high triglyceride content arising from the thoracoabdominal lymph nodes in the peritoneal cavity due to various benign or malignant etiologies, including pancreatic cancer. During cancer chemotherapy, the accumulation of ascites can lead to the deterioration of the patient's general condition, making chemotherapy administration difficult, and resulting in a poor prognosis. We encountered a rare case of chylous ascites complicated by advanced pancreatic cancer. The patient presented with a discrepancy between the shrinkage of the pancreatic cancer and the accumulation of ascites. Therefore, we were able to promptly diagnose chylous ascites by performing biochemical tests. The patient was treated with octreotide, reportedly effective in treating chylous ascites, which rapidly improved the chylous ascites and general condition of the patient, allowing the patient to continue chemotherapy for pancreatic cancer. Therefore, physicians should consider the possibility of chylous ascites when clinically unexplained ascites are observed in patients with advanced cancer. The investigation and treatment of chylous ascites should be initiated as soon as possible.

Indexed as

Chylous AscitesPancreatic NeoplasmsAscitesHumansLymph NodesOctreotideOctreotidechemotherapychylous ascitesoctreotidepancreatic cancer

Identifiers

PMID38534945
PMCPMC10969774
OpenAlexW4392696956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.